NCT07503808 A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 150 participants in total. It began in 2026-02-24 with a primary completion date of 2027-07-30.

Brief Summary

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Eligibility Criteria

Inclusion Criteria: 1. Participant must be at least 18 years of age or the age of maturity per local regulations 2. Participants with advanced recurrent or metastatic solid tumors expressing B7-H3 and PTK7 in the following indications: NSCLC, ESCC, endometrial cancer, HGSOC, HNSCC, TNBC (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \[HER2\] negative), CRC, and CRPC who have radiologically progressed or recurred on at least one line of therapy or is intolerant to additional effective standard therapies. 3. Archival tissue sample for testing 4. Measurable disease 5. Have Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. 6. Have adequate bone marrow and organ function. 7. Able to comply with contraceptive/barrier requirements Exclusion Criteria: 1. Known symptomatic brain metastases or leptomeningeal metastasis 2. Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose. 3. Have uncontrolled tumor-associated pain 4. Have clinically significant cardiac abnormalities and/or cerebrovascular disease (stroke) within 6 months before the first dose 5. Active uncontrolled infection 6. Have history of interstitial pneumonitis, current noninfectious pneumonitis requiring steroid therapy; known or suspected interstitial pneumonitis as seen on screening imaging; other moderate to severe lung diseases seriously affecting respiratory function within 3 months before the first dose. 7. Have history of severe infections within 4 weeks prior to the start of study treatment, including but not limited to bacteremia, severe pneumonia, or other serious infectious complications requiring hospitalization. 8. Have history of immunodeficiency, with a positive human immunodeficiency virus (HIV) test at screening. 9. Participants with known or suspected viral hepatitis 10. Have history of active tuberculosis within 1 year before enrollment 11. If participants had adverse reactions to previous antitumor treatment that have not recovered to guidelines of CTCAE Grade ≤ 1 and Grade 2 peripheral neurological symptoms 12. Have received chemotherapy within 3 weeks of first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 3 weeks before the first dose of IMP or other investigational products within 4 weeks of first dose of IMP 13. Administration of any of the following 1. Current use or anticipated need for food or drugs that are known strong CYP3A4/5 inhibitors or inducers 2. Have prior treatment with B7-H3 or PTK7 antibody-drug conjugate (ADC). 3. Have prior treatment with a topoisomerase I inhibitor (TOP1i), including an ADC with a TOP1i payload, within 6 months of first dose of IMP 4. Have received radiotherapy within 2 weeks prior to study entry 5. Have undergone major surgery or trauma within 4 weeks prior to study entry. 6. Have received live attenuated vaccine within 28 days prior to the first dose or are expected to receive live attenuated vaccine during the study treatment. 7. Female participants who are pregnant, lactating, or planning to become pregnant during the study period to 7 months after the last dose of IMP. 8. Are known to be allergic to any component or excipient of the IMP product or have a history of severe allergic reactions to other monoclonal antibody/fusion protein drugs. 9. Participants with complications in the eye including ulcers in the eye, and severe dry eye

Contact & Investigator

Frequently Asked Questions

Related Trials